Olympus America

Press Center

Dade Behring and Olympus Sign Agreement for Continued Distributorship in the Drugs-of-Abuse Market

Reaffirms successful partnership in drugs-of-abuse business for high-volume toxicology laboratories

Deerfield, IL, September 22, 2005 - Dade Behring (NASDAQ: DADE), the world's largest company solely dedicated to clinical diagnostics and the leader in the drugs-of-abuse testing market, and Olympus America, which offers the broadest line of chemistry/ immunochemistry systems, today announced that they have signed an agreement to extend their longstanding partnership enabling Dade Behring to sell Olympus instrumentation together with Dade Behring Syva-Emit® branded assays. This 5-year agreement allows Dade Behring and Olympus to continue their distributor relationship in a defined U.S. drugs-of-abuse and toxicology market. Under the agreement, Dade Behring sells Olympus instruments and service to Dade Behring customers, thereby offering customers the only complete line of drugs-of-abuse tests and analytical systems for low to the very highest-volume toxicology laboratory.

"Together, under this agreement, we can expand the range of innovative, high-quality solutions we offer to our customers in the toxicology and specialty labs," said Jim Reid-Anderson, Dade Behring's Chairman, President and CEO. "This agreement gives laboratorians access to a solution focused on their specific needs in the drugs-of-abuse laboratory, from two of the leading companies in the industry today. We greatly value our long partnership with Olympus and look forward to continued expansion of the range of relevant, high-quality innovations we offer to our customers."

"Laboratory professionals are seeking comprehensive approaches to their needs, and this customer-focused relationship extends what is already a highly successful affiliation with Syva," said Stephen Wasserman, Group Vice President, Olympus America Inc. Diagnostic Systems Group. "As this agreement demonstrates, Olympus analyzers provide flexible and reliable solutions for hospital and clinical labs of every size. In fact, more drugs-of-abuse-in urine (DAU) testing is performed on Olympus analyzers than any other brand of instrument."

The agreement also assures that Dade Behring will have complete access to the entire Olympus instrument line, which includes the AU400®, AU640®, AU2700®, and the AU5400® series analytical systems. In conjunction with Dade Behring's 45 Syva-Emit® branded tests, this will provide drugs-of-abuse customers with the broadest range of tests and instrumentation available to the toxicology market. Olympus analyzers are capable of performing more drugs-of-abuse-in urine (DAU) tests than any other line of instrumentation.

Under the Syva® brand name, Dade Behring offers tests that either detect or provide quantitative measures of therapeutic drugs, drugs-of-abuse, and drugs used to prevent rejection of transplanted organs. Monitoring proper dosages of therapeutic drugs is essential for patient assessment in critical care situations, for pre-employment screening processes, and as evidence in legal proceedings. The Syva® name remains, after more than two decades, the leading brand in the drugs-of-abuse market segment.

About Dade Behring
With 2004 revenues of nearly $1.6 billion, Dade Behring is the world's largest company dedicated solely to clinical diagnostics. It offers a wide range of products, systems and services designed to meet the day-to-day needs of labs, delivering innovative solutions to customers and enhancing the quality of life for patients. Additional company information is available on the internet at www.dadebehring.com.

About Olympus Diagnostic Systems Group
Olympus Diagnostic Systems Group provides innovative solutions that meet the high productivity demands of hospitals, integrated healthcare delivery networks, reference labs, blood banks and pharmaceutical labs. Olympus offers the broadest standardized line of random access chemistry-immuno analyzers, along with lab automation systems, comprehensive patient safety systems, blood bank analyzers and reagents. Olympus solutions save laboratories time, enhance patient safety, maximize productivity, and deliver fast, reliable results.

About Olympus
Olympus is a precision technology leader, designing and delivering innovative solutions in healthcare and consumer electronics worldwide.

Olympus works collaboratively with its customers and its parent company, Tokyo-based Olympus Corporation, to leverage R&D investment in precision technology and manufacturing processes across diverse business lines. These include:

  • Gastrointestinal endoscopes, accessories, and minimally invasive surgical products;
  • Advanced clinical and research microscopes;
  • Lab automation systems, chemistry-immuno and blood bank analyzers and reagents; and
  • Digital and film cameras, and digital voice recorders.

In the U. S. and Canada, Olympus serves healthcare, scientific and commercial laboratory markets with integrated product solutions and financial, educational and consulting services that help customers efficiently, reliably, safely, and easily achieve superior results. Olympus is the leader in gastrointestinal endoscopy and clinical and educational microscopes. The company's market-leading consumer electronics business spans North and South America. For more information, visit www.olympusamerica.com.